Engineered donor T-cells become a living drug to beat untreatable leukemia

A world-first therapy edits donor T-cells with a base-editing CRISPR approach to target T-cell leukemia, turning white blood cells into a disease-fighting living drug. In early tests at GOSH and King’s College Hospital, nine children and two adults showed deep remissions, with seven remaining disease-free three years later.